X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
STAR-0215 is a monoclonal antibody dug candidate that acts as inhibitor of plasma kallikrein, which is being evaluated for the treatment of hereditary angioedema.
Lead Product(s): STAR-0215
Therapeutic Area: Genetic Disease Product Name: STAR-0215
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 25, 2024
Details:
The company intends to use the net proceeds for research and development activities, including clinical development of STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, and preclinical and clinical development of STAR0310, a monoclonal antibody OX40 antagonist.
Lead Product(s): STAR-0215
Therapeutic Area: Genetic Disease Product Name: STAR-0215
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: RA Capital Management
Deal Size: $125.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 30, 2024
Details:
Under the terms of the license agreement, Astria plans to develop the lead candidate, called STAR-0310, a monoclonal antibody OX40 antagonist that incorporates YTE half-life extension technology, for the treatment of AD.
Lead Product(s): STAR-0310
Therapeutic Area: Dermatology Product Name: STAR-0310
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Ichnos Sciences
Deal Size: $320.0 million Upfront Cash: $15.0 million
Deal Type: Licensing Agreement October 11, 2023
Details:
STAR-0215 is a monoclonal antibody inhibitor of plasma kallikrein in development for the treatment of HAE. The Phase 1b/2 ALPHA-STAR trial evaluating STAR-0215 in HAE patients is ongoing, with proof-of-concept results expected in mid-2024.
Lead Product(s): STAR-0215
Therapeutic Area: Genetic Disease Product Name: STAR-0215
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 20, 2023
Details:
The Company expects to use the net proceeds from the Offering, for the advancement of the Company’s clinical development programs, including STAR-0215 and for working capital and other general corporate purposes.
Lead Product(s): STAR-0215
Therapeutic Area: Genetic Disease Product Name: STAR-0215
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Jefferies
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 09, 2023
Details:
STAR-0215 is a monoclonal antibody inhibitor of plasma kallikrein, it is currently under development for the treatment of hereditary angioedema (HAE).
Lead Product(s): STAR-0215
Therapeutic Area: Genetic Disease Product Name: STAR-0215
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 08, 2023
Details:
STAR-0215 is a monoclonal antibody inhibitor of plasma kallikrein designed to provide long-acting, effective HAE attack prevention.
Lead Product(s): STAR-0215
Therapeutic Area: Genetic Disease Product Name: STAR-0215
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2022
Details:
STAR-0215, is a potential best-in-class monoclonal antibody inhibitor of plasma kallikrein that is in clinical development for the treatment of hereditary angioedema.
Lead Product(s): STAR-0215
Therapeutic Area: Genetic Disease Product Name: STAR-0215
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 16, 2022
Details:
Preclinically, STAR-0215 has been shown to be a long-acting, potent, and selective inhibitor of plasma kallikrein. In a study conducted in cynomolgus monkeys, STAR-0215 showed rapid inhibition of plasma kallikrein after subcutaneous administration.
Lead Product(s): STAR-0215
Therapeutic Area: Genetic Disease Product Name: STAR-0215
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 04, 2022
Details:
STAR-0215 is an investigational monoclonal antibody inhibitor of plasma kallikrein designed to provide long-acting, effective attack prevention for HAE with dosing once every 3 months or longer.
Lead Product(s): STAR-0215
Therapeutic Area: Genetic Disease Product Name: STAR-0215
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 28, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
